他泽司他是治疗什么病的？

Tazverik (trade name: Tazverik) is an oral EZH2 inhibitor jointly developed by the American biopharmaceutical company Epizyme and Japan's Eisai Co., Ltd. It was approved for accelerated marketing in the United States in January 2020 and is used to treat patients 16 years old and above with unresectable metastatic or locally advanced ES. This is the world's first drug specifically used to treat epithelioid sarcoma (ES). Based on the performance of tazerestat in patients with follicular lymphoma (FL), the U.S. Food and Drug Administration (FDA) accepted a supplemental application for the treatment of FL in February 2020, and approved a new indication of this drug in adult patients with EZH2-positive relapsed or refractory FL on June 18.

Tazemetostat inhibits EZH2 and acquired mutations of EZH2 (including Y646X and A687V) through competitive inhibition with S-adenosyl-L-methionine (SAM), a cofactor essential for EZH2 function. At the same time, tazerestat can also inhibit EZH1, and its half inhibitory concentration (IC50) is 392 nM. This inhibitory concentration is 36 times that of EZH2.

800 mg/d, bid, until disease progression or unacceptable toxicity. Tazerestat should be swallowed whole. If you forget to take the medicine or vomit after taking the medicine, do not take the medicine again, but continue to take the next scheduled dose. The side effects of tazetostat include nausea, upper respiratory tract infection, fatigue, musculoskeletal pain, constipation, vomiting, pain, decreased appetite, and abdominal pain. If serious adverse reactions occur during the use of tazerestat and are intolerable, it is recommended that the patient go to the hospital immediately for examination and consult the relevant attending physician to determine the subsequent treatment plan based on his or her own situation. During the medication period, it is also important not to misuse the medication or change the medication time and dosage without authorization, so as not to delay your own treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.